Course Information

Release date: August 1, 2025
Expiration date: August 1, 2026
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

Provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

PROGRAM OVERVIEW

Hereditary angioedema (HAE) is a rare autosomal-dominant disorder that affects approximately 1 in 50,000 people worldwide. Individuals with HAE typically experience recurrent painful swelling of the extremities, face, or genitals, in addition to gastrointestinal attacks and potentially fatal laryngeal edema. Furthermore, these swelling episodes are often associated with disfigurement, significant functional impairment, and decreased quality of life (QOL). Despite the existence of specific diagnostic criteria, diagnosis may be delayed by up to 15 years, leading to delays in optimal treatment with available on-demand and prophylactic therapies. Additionally, several novel agents are in development. Given the range of treatment options (eg, formulations, administration routes, dosing strategies), timely diagnosis and personalized treatment plans and a shared decision-making approach are essential to ensure appropriate utilization of prescribed treatment and quick recovery from attacks.

Join our expert faculty in this case-based activity to explore a tailored approach that not only enhances treatment adherence and efficacy but also significantly improves patient QOL, ensuring that clinicians can better address the complexities of HAE to promote improved health outcomes and reduced morbidity.

Learning Objectives

TARGET AUDIENCE

This educational activity has been designed to meet the needs of allergists, immunologists, nurse practitioners, physician assistants, and other healthcare providers who manage patients with HAE.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Apply guideline-recommended strategies to accurately identify patients with HAE
Analyze and compare approved and emerging treatment options for managing HAE effectively
Utilize shared decision-making and validated assessment tools in the development of treatment plans for patients with HAE

Faculty Information and Disclosures

FACULTY

Maeve O’Connor, MD, FACAAI, FAAAAI, FACP

Clinical Assistant Professor, University of North Carolina - Charlotte Department of Public Health Sciences

Clinical Adjunct Professor, University of Arizona-Tucson

Department of Integrative Medicine

Medical Director, Integrative Allergy & Immunology Care, LLC

Medical Director and Principal Investigator, Allergy Asthma & Immunology Research Institute

Chief Medical Officer, Consortium of Independent Immunology Clinics

Chief Medical Officer, Alexander Innovations International

Nicholas C. Kolinsky, DO

Clinical Adjunct Faculty

Allergy and Immunology

Lincoln Memorial University-DeBusk College of Osteopathic Medicine

Harrogate, Tennessee

President-Elect, Tennessee Society of Allergy, Asthma, and Immunology

Knoxville, Tennessee

Neetu Talreja, MD, FAAAAI, FACAAI

Board Certified Pediatric and Adult Allergist and Immunologist

The Allergy Group

Boise, Idaho

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Nicholas C. Kolinsky, DO

Advisory Boards: ADMA Biologics, AstraZeneca, Hikma Pharmaceuticals, KalVista Pharmaceuticals, Novartis Pharmaceuticals, Pharming

Speaker: Amgen, AstraZeneca, CSL Behring, GlaxoSmithKline, Hikma Pharmaceuticals, Sanofi Pharmaceuticals

Maeve O’Connor, MD, FACAAI, FAAAAI, FACP

Advisory Boards: ADMA, Amgen, AstraZeneca, Blueprint, Cogent, CSL Behring, GlaxoSmithKline, KalVista, Novartis, Optinose, Pharming, Regeneron, Sanofi, Takeda

Consultant/Speaker: ADMA, Amgen, AstraZeneca, Blueprint, Cogent, CSL Behring, GlaxoSmithKline, KalVista, Novartis, Optinose, Pharming, Regeneron, Sanofi, Takeda

Research: ADMA, Amgen, AstraZeneca, Blueprint, Cogent, CSL Behring, GlaxoSmithKline, KalVista, Novartis, Optinose, Pharming, Regeneron, Sanofi, Takeda

Neetu Talreja, MD, FAAAAI, FACAAI

Advisory Boards: Regeneron, Novartis, Celldex, Incyte

Speaker: ARS Pharmaceuticals

Research: 9Meters, Abbvie, Allakos, Amgen, Anaptybio, Arcutis, Arena, ARS Pharma, AstraZeneca, Biohaven, Blueprint, Braintree Laboratories Inc., Castle Biosciences Inc., Celldex Therapeutics, Cindome Pharma, Inc., Eli Lilly and Company, Escient Pharmaceuticals, Inc., Evommune Inc., Gossamer, GlaxoSmithKline, Incyte Co., Jasper Therapeutics Inc., Knopp, Nerre, Novartis Pharmaceuticals, Pearl Therapeutics, Pfizer, Phathom, Regeneron Pharmaceuticals, Sanofi-Aventis Recherche & Developpement, Seres, Teva Branded Pharmaceutical Products R&D, Uniquity One, Upstream Bio, Inc

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of August 1, 2025 through August 1, 2026, participants must:

Read the learning objectives
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Internet: Stable connection
Operating Systems: Windows 10/macOS 10.14 or later recommended
Web Browser: Latest versions of Google Chrome, Microsoft Edge, or Safari recommended (other modern browsers also supported)
Plug-ins: No plug-ins required
For optimal performance and security, ensure your browser is up to date and avoid using unsupported or outdated versions

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: August 1, 2025Expiration date: August 1, 2026Estimated time to complete activity: 60 minutes

Evolving Strategies for the Management of Hereditary Angioedema – A Patient-Centered Approach With Real-World Examples